BASF’s Insider Buying Spree Raises Eyebrows as Analysts Clash Over Valuation
12.05.2026 - 13:24:23 | boerse-global.de
A flurry of share purchases by top BASF executives has added a layer of corporate conviction to a stock already riding a 19% year-to-date gain. But the surge in insider activity arrives at a moment when the chemicals giant is trading dangerously close to its 52-week high and facing a sharp divide among sell-side analysts.
Four senior figures—Dr. Kurt Bock, Dr. Katja Scharpwinkel, Prof. Dr. Stefan Asenkerschbaumer, and Dr. Stephan Kothrade—have recently disclosed directors’ dealings, buying shares in both the management board and supervisory board. Their purchases come as the stock sits at €53.57, just 2% below the year’s peak of €54.70. The timing is notable: rather than scooping up shares after a rout, insiders are loading up near the top of the recent trading range, a move that suggests they see further upside where others may not.
Yet the technical picture tells a different story. The stock now trades comfortably above its 200-day moving average, and the relative strength index stands at 73.8—firmly in overbought territory. The average analyst price target compiled in April 2026 stands at €49.81, a level the stock has already surpassed by more than 7%.
Should investors sell immediately? Or is it worth buying BASF?
The analyst community itself is split. Goldman Sachs analyst Georgina Fraser lifted her price target from €63 to €65, maintaining a “Buy” rating on the back of better-than-expected first-quarter numbers. BASF reported EBITDA before special items of €2.4 billion for Q1 2026, with revenue of around €16 billion—barely 3% below the prior-year quarter, hit mainly by currency headwinds from the US dollar and Chinese renminbi. Fraser’s upgrade reflects upward revisions to her earnings estimates.
At the same time, LBBW took a more cautious stance, downgrading BASF from “Buy” to “Hold” while raising its target from €51 to €56. The conflicting signals underscore how difficult it is to value a cyclical chemical company whose fortunes remain tied to industrial demand, energy costs, and global supply chains—dynamics that insider purchases alone cannot rewrite.
Adding to the narrative, BASF’s buyback program is humming along. In the week from May 4 to 8 alone, the company repurchased nearly 4.8 million of its own shares. Since the program launched in November 2025, the tally has reached roughly 24.3 million shares. The current tranche, worth up to €1.5 billion, is scheduled to wrap up by the end of June 2026. That is just one piece of a larger shareholder return pledge: BASF plans to deploy a total of €4 billion on buybacks through 2028, complemented by dividends of at least €2.25 per share annually. All told, management has promised investors no less than €12 billion in total distributions by 2028.
Finance chief Dirk Elvermann put his own money behind that commitment on May 8, snapping up BASF shares on Tradegate at €50.91 for a total outlay of nearly €46,000. The purchase aligns with a broader wave of insider confidence, but operational delivery remains the real test. The company confirmed its full-year outlook after the first quarter, and the structural transformation continues: since May 2026, BASF has been running its agricultural business as a stand-alone unit, with a Frankfurt IPO penciled in for 2027. For now, the stock’s momentum is backed by management’s wallet—but whether that can sustain a share price already above consensus forecasts is the question hanging over the next move.
Ad
BASF Stock: New Analysis - 12 May
Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
So schätzen die Börsenprofis BASF’s Aktien ein!
FĂĽr. Immer. Kostenlos.
